Welcome to our dedicated page for Adlai Nortye Ltd. American Depositary Shares news (Ticker: ANL), a resource for investors and traders seeking the latest updates and insights on Adlai Nortye Ltd. American Depositary Shares stock.
Adlai Nortye Ltd. (NASDAQ: ANL) is a clinical-stage biotechnology company dedicated to discovering and developing innovative cancer therapies for patients across a wide range of tumor types. The company’s robust pipeline includes both clinical and preclinical drug candidates, with notable projects such as buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
Founded with a strategic focus on oncology, Adlai Nortye has established global R&D centers in New Jersey and Hangzhou. The company is committed to becoming a leader in the next wave of immuno-oncology therapies, specifically employing a combination therapy strategy to transform deadly cancer into a chronic and ultimately curable disease.
In recent news, Adlai Nortye successfully priced its initial public offering (IPO) of 2,500,000 American depositary shares (ADSs) on September 29, 2023. The offering raised gross proceeds of approximately $97.5 million. Additionally, Adlai Nortye has strengthened its position through strategic partnerships with leading pharmaceutical companies like Eisai and Novartis, maximizing the potential of its pipeline programs.
Adlai Nortye's significant achievements include the completion of patient enrollment in the global Phase III BURAN trial, evaluating buparlisib (AN2025) for the treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The company also received the ESMO 2023 Best Poster Award for a study predicting response to Buparlisib in SCCHN using AI-based digital pathology.
With an experienced management team and advisory board comprising industry leaders and influential scientists, Adlai Nortye is well-positioned to advance its mission. The company continues to explore and secure partnerships while building its R&D capabilities to deliver innovative cancer therapies worldwide.
For more detailed and up-to-date information, visit the company's official website at www.adlainortye.com.
Adlai Nortye (NASDAQ: ANL) reported its unaudited first half 2024 financial results and recent operational progress. Key highlights include:
1. Appointment of Roger Sawhney, M.D. to the Board of Directors
2. Encouraging safety and efficacy data for AN4005, an oral PD-L1 inhibitor
3. On track to report Phase 3 OS data for buparlisib in Q1 2025
4. Cash and cash equivalents of $98.0 million as of June 30, 2024
5. Net loss decreased by 64.8% to $27.7 million for H1 2024
6. R&D expenses decreased by 4.5% to $26.0 million
7. G&A expenses decreased by 9.8% to $4.7 million
The company remains focused on advancing its pipeline of targeted and immune-modulating cancer therapies.
Adlai Nortye (NASDAQ: ANL), a global clinical-stage biotechnology company, has appointed Roger Sawhney, M.D. to its Board of Directors, effective August 8, 2024. Dr. Sawhney brings nearly 30 years of financial and strategic expertise in the biopharma industry. He currently serves as the Chief Financial Officer of LB Pharmaceuticals and has held leadership positions at various pharmaceutical and investment firms, including Garuda Therapeutics, Omega Therapeutics, KKR & Co. Inc., and Novartis AG.
CEO Carsten Lu welcomed Dr. Sawhney, highlighting his valuable financial experience from both pharmaceutical corporate and healthcare investment perspectives. Dr. Sawhney expressed enthusiasm for joining Adlai Nortye's mission to develop innovative cancer therapies and transform deadly cancer into a chronic and eventually curable disease.
Adlai Nortye (NASDAQ: ANL) has announced its plans to present preliminary data of AN0025 in combination with definitive chemoradiotherapy (dCRT) at the ASCO 2024 Annual Meeting in Chicago from May 31 to June 4, 2024. AN0025, a selective EP4 inhibitor, has shown antitumor activity by modulating macrophages and immunosuppressive myeloid cells. The study, AN0025S0104, is a single-arm, open-label, multicenter, Phase Ib trial, assessing the safety, tolerability, and feasibility of AN0025 plus dCRT for unresectable locally advanced or recurrent esophageal cancer (EC) and esophagogastric junction cancer. Previous studies highlighted the synergistic efficacy of AN0025 with CRT in rectal cancer. Adlai Nortye aims to address unmet patient needs through innovative oncology research.
Adlai Nortye announced the dosing of the first patient in its Phase II clinical trial, named ARTEMIS, for palupiprant (AN0025) in treating locally advanced rectal cancer. This study, led by the Cancer Research UK Clinical Trials Unit at the University of Leeds, aims to compare total neoadjuvant therapy (TNT) with or without AN0025 in patients with moderate to high-risk rectal cancer. The trial involves 140 patients, divided into two groups, and will evaluate clinical complete response (cCR) rate six months post-radiotherapy. The trial builds on encouraging Phase Ib results and seeks to improve efficacy while minimizing invasive surgeries.
FAQ
What is the current stock price of Adlai Nortye Ltd. American Depositary Shares (ANL)?
What is the market cap of Adlai Nortye Ltd. American Depositary Shares (ANL)?
What is Adlai Nortye Ltd.?
What is the core focus of Adlai Nortye?
What are some key products in Adlai Nortye's pipeline?
What recent achievements has Adlai Nortye announced?
Where are Adlai Nortye's R&D centers located?
What strategic partnerships has Adlai Nortye formed?
What was the outcome of the ESMO 2023 Best Poster Award?
What is the goal of Adlai Nortye's combination therapy strategy?
How can I get more information about Adlai Nortye?
What is the significance of buparlisib (AN2025) in Adlai Nortye's pipeline?
